Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGUS trial of EPX-100 adjunctive therapy in Dravet syndrome
CTR20260716Phase 3Active
- Sponsor
- N/A/ 元羿生物科技（上海）有限公司
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of clemizole in Dravet syndrome, sponsored by N/A/ 元羿生物科技（上海）有限公司. Started Jun 2026; status: active.
02
Drugs
clemizole
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on CTR20260716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260716.